Key result
Diabetic patients had a significantly higher percentage of monocyte-platelet aggregates compared to controls (Type 1: 43.0%, Type 2: 34.9% vs control: 24.6%; P<0.01 and P<0.5, respectively).
Why the study?
Does the number of circulating leukocyte-platelet heterophilic aggregates differ between diabetic patients and controls?
Population
90 diabetic patients (Type 1, n=29; Type 2, n=61) and 23 control subjects
Comparison
Measurement of circulating leukocyte-platelet… vs Healthy control subjects
Design
Case-control
Authors
Loading...
May mark prothrombotic state in diabetes; hypothesis-generating and should not yet change practice.
Observational (n=113)
Does the number of circulating leukocyte-platelet heterophilic aggregates differ between diabetic patients and controls?
p-value: p=<0.01
Monocyte-platelet aggregates are significantly elevated in diabetic patients, particularly those with microvascular complications, suggesting a potential role in the pathogenesis of diabetic angiopathy.
Káplár et al. (2001) conducted an observational in Diabetes (n=113). Diabetes vs. Control subjects was evaluated on Percentage of monocyte-platelet aggregates (p=<0.01). Diabetic patients had a significantly higher percentage of monocyte-platelet aggregates compared to controls (Type 1: 43.0%, Type 2: 34.9% vs control: 24.6%; P<0.01 and P<0.5, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: